Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Aadi Bioscience, Now Whitehawk Therapeutics Reports Q4 2024 GAAP EPS $(0.67) Misses $(0.35) Estimate, Sales $7.239M Up From $6.326M YoY

Author: Benzinga Newsdesk | March 19, 2025 08:55am
Aadi Bioscience (NASDAQ:AADI) reported quarterly losses of $(0.67) per share which missed the analyst consensus estimate of $(0.35) by 91.43 percent. This is a 11.67 percent decrease over losses of $(0.60) per share from the same period last year. The company reported quarterly sales of $7.24 million which missed the analyst consensus estimate of $7.37 million by 1.78 percent. This is a 14.43 percent increase over sales of $6.33 million the same period last year.

Posted In: AADI WHWK


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist